At close: December 20 at 4:00:02 PM EST
After hours: December 20 at 6:44:50 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
--
--
2,014.0000
Operating Expense
20,314.0000
21,159.0000
18,137.0000
14,221.0000
11,600.0000
Operating Income
-20,314.0000
-21,159.0000
-18,137.0000
-14,221.0000
-9,586.0000
Net Non Operating Interest Income Expense
662.0000
640.0000
-2.0000
-4.0000
-8.0000
Other Income Expense
950.0000
2,535.0000
-20,698.0000
40.0000
-54.0000
Pretax Income
-18,702.0000
-17,984.0000
-38,837.0000
-14,185.0000
-9,648.0000
Net Income Common Stockholders
-18,702.0000
-17,984.0000
-38,837.0000
-14,185.0000
-9,648.0000
Diluted NI Available to Com Stockholders
-18,702.0000
-17,984.0000
-38,837.0000
-14,185.0000
-9,648.0000
Basic EPS
-1.84
-1.87
-4.77
-0.16
-2.04
Diluted EPS
-1.84
-1.87
-4.77
-0.16
-2.04
Basic Average Shares
10,185.7500
9,651.0000
8,143.0000
7,364.0000
4,601.4160
Diluted Average Shares
10,185.7500
9,651.0000
8,143.0000
7,364.0000
4,601.4160
Total Operating Income as Reported
-19,314.0000
-18,559.0000
-38,829.0000
-14,221.0000
-9,586.0000
Total Expenses
20,314.0000
21,159.0000
18,137.0000
14,221.0000
11,600.0000
Net Income from Continuing & Discontinued Operation
-18,702.0000
-17,984.0000
-38,837.0000
-14,185.0000
-9,648.0000
Normalized Income
-19,652.0000
-20,519.0000
-18,139.0000
-14,225.0000
-9,594.0000
Interest Expense
--
--
2.0000
4.0000
8.0000
Net Interest Income
662.0000
640.0000
-2.0000
-4.0000
-8.0000
EBIT
-20,314.0000
-21,159.0000
-18,137.0000
-14,181.0000
-9,640.0000
EBITDA
-20,314.0000
-21,159.0000
-17,749.0000
-13,799.0000
-9,483.0000
Reconciled Depreciation
-1,355.0000
-1,388.0000
388.0000
382.0000
157.0000
Net Income from Continuing Operation Net Minority Interest
-18,702.0000
-17,984.0000
-38,837.0000
-14,185.0000
-9,648.0000
Total Unusual Items Excluding Goodwill
950.0000
2,535.0000
-20,698.0000
40.0000
-54.0000
Total Unusual Items
950.0000
2,535.0000
-20,698.0000
40.0000
-54.0000
Normalized EBITDA
-21,264.0000
-23,694.0000
2,949.0000
-13,839.0000
-9,429.0000
-
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
HEPA Hepion Pharmaceuticals, Inc.
0.4900
-7.56%
CDTX Cidara Therapeutics, Inc.
23.22
+3.15%
EDSA Edesa Biotech, Inc.
1.7300
-1.14%
DYAI Dyadic International, Inc.
1.7500
-8.14%
ENVB Enveric Biosciences, Inc.
0.3250
+1.25%
SPRC SciSparc Ltd.
0.2133
-0.19%
VCNX Vaccinex, Inc.
1.4100
0.00%
LPTX Leap Therapeutics, Inc.
2.9100
+4.68%
ENTX Entera Bio Ltd.
2.1000
-3.23%
BLPH Bellerophon Therapeutics, Inc.
0.0120
-36.84%